Zhittya Genesis Medicine announces: Free Zoom Webinar: Zhittya Parkinson’s Disease Research Study: 6-Month Patient Follow-Up Report LAS VEGAS, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that they will be hosting a webinar on Tuesday, December 20, 2022, at 4:00 PM...

Zhittya Genesis Medicine Announces: Parkinson’s Disease Sufferers Motor Skills Improved by 50% After Medical Research Study LAS VEGAS, June 16, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that the human test subjects in its first-in-human research study for the...

Zhittya Genesis Medicine Completes its First-In-Human Study with a Novel Intranasal Treatment for Parkinson’s Disease LAS VEGAS, June 08, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that it has completed its first-in-human research study for the treatment of...

Neuronascent Receives FDA Orphan Drug Designation for NNI-351 Treatment of Fragile X Syndrome ROCKVILLE, Md., June 01, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc, today announced that the U.S. Food and Drug Administration (FDA) granted “Orphan Drug Designation” for the company’s NNI-351...

Neuronascent Receives State and Federal Funding for Its Neurogenesis Therapeutic Programs CLARKSVILLE, MD--(Marketwire - Jun 2, 2011) - Neuronascent, Inc. announced today that the Company has received funding from both the federal government, under the Qualifying Therapeutic Discovery...